Angiogenesis as a target for cancer therapy

Hematology/Oncology Clinics of North America

Volumn 16, Issue 5, 2002, Pages 1125-1171

  Kaban, Kerim ^a   Herbst, Roy S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; 4 DEDIMETHYLAMINOSANCYCLINE; AE 941; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BEVACIZUMAB; CANERTINIB; CELECOXIB; CETUXIMAB; CILENGITIDE; CYTOTOXIC AGENT; ENDOSTATIN; ERLOTINIB; FUMAGILLOL CHLOROACETYLCARBAMATE; GEFITINIB; IM 862; IMC IC11; LONAFARNIB; MARIMASTAT; MONOCLONAL ANTIBODY; PANITUMUMAB; PRINOMASTAT; ROFECOXIB; SEMAXANIB; THALIDOMIDE; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN INHIBITOR; ANTINEOPLASTIC AGENT; COLLAGEN; EPHRIN; EPHRIN RECEPTOR; GROWTH FACTOR RECEPTOR; GROWTH PROMOTOR; LIGASE; MATRIX METALLOPROTEINASE; PEPTIDE FRAGMENT; PLASMINOGEN; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEINASE INHIBITOR; THROMBOSPONDIN; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE; VHL PROTEIN, HUMAN; VITRONECTIN RECEPTOR; VON HIPPEL LINDAU PROTEIN;

AGITATION; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ATAXIA; BACKACHE; BRADYCARDIA; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOTENSION; INSOMNIA; LUNG HEMORRHAGE; MEMORY DISORDER; MYALGIA; NAUSEA; NONHUMAN; PERICARDITIS; PERIPHERAL NEUROPATHY; PLEURISY; PRIORITY JOURNAL; PROTEINURIA; RASH; REVIEW; RISK BENEFIT ANALYSIS; STROKE; THORAX PAIN; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; ANIMAL; CELL HYPOXIA; CHILD; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; IMMUNOTHERAPY; MOUSE; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); OUTCOME ASSESSMENT; PATHOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANGIOSTATINS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTICARCINOGENIC AGENTS; CELL HYPOXIA; CHILD; CLINICAL TRIALS; COLLAGEN; CYCLOOXYGENASE INHIBITORS; DRUG DESIGN; ENDOSTATINS; ENDOTHELIUM, VASCULAR; EPHRINS; GROWTH SUBSTANCES; HUMANS; IMMUNOTHERAPY; INTEGRIN ALPHAVBETA3; LIGASES; MATRIX METALLOPROTEINASES; MICE; NEOPLASM PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OUTCOME ASSESSMENT (HEALTH CARE); PEPTIDE FRAGMENTS; PLASMINOGEN; PROTEASE INHIBITORS; RECEPTORS, EPH FAMILY; RECEPTORS, GROWTH FACTOR; THROMBOSPONDINS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 0036817490     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(02)00047-3     Document Type: Review

References (299)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
2. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
3. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182-6.
4. th Edition. London: B.C. Decker Inc.; 2000. p. 132-52.
5. Li CY, Shan S, Huang Q, et al. Initial stages of tumor cell-induced angiogenesis: Evaluation via skin window chambers in rodent models. J Natl Cancer Inst 2000;92:143-7.
6. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
7. Boehm T, Folkman J, Browder T, et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:404-7.
8. Moses MA. The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Stem Cells 1997;15:180-9.
9. Rupp PA, Little CD. Integrins in vascular development. Circ Res 2001;89:566-72.
10. Cheng N, Brantley DM, Chen J. The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor Rev 2002;13:75-85.
11. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997;277:55-60.
12. Suri C, McClain J, Thurston G, et al. Increased vascularization in mice overexpressing angiopoietin-1. Science 1998;282:468-71.
13. Thurston G, Suri C, Smith K, et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 1999;286:2511-4.
14. Karkkainen MJ, Makinen T, Alitalo K. Lymphatic endothelium: A new frontier of metastasis research. Nat Cell Biol 2002;4:E2-5.
15. Bouck N, Stellmach V, Hsu SC. How tumors become angiogenic. Adv Cancer Res 1996;69:135-74.
16. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
17. Bellamy WT. Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. Semin Oncol 2001;28:551-9.
18. Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis: Signaling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 2001;22:201-7.
19. Doll JA, Reiher FK, Crawford SE, et al. Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate. Prostate 2001;49:293-305.
20. Shou Y, Hirano T, Gong Y, et al. Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer. Br J Cancer 2001;85:1706-12.
21. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.
22. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.
23. Volpert OV, Lawler J, Bouck NP. A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1. Proc Natl Acad Sci U S A 1998;95: 6343-8.
24. Ferrara N, Gerber HP. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol 2001;106:148-56.
25. Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 1998;273: 13313-6.
26. Liu WL, Guo X, Chen QQ, et al. VEGF protects bovine aortic endothelial cells from TNF-[alpha]- and H(2)O(2)-induced apoptosis via co-modulatory effects on p38-and p42/p44-CCDPK signaling. Acta Pharmacol Sin 2002;23:45-9.
27. Claesson-Welsh L, Welsh M, Ito N, et al. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc Natl Acad Sci U S A 1998;95:5579-83.
28. Jimenez B, Volpert OV, Crawford SE, et al. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000;6:41-8.
29. Liu LX, Lu H, Luo Y, et al. Stabilization of vascular endothelial growth factor mRNA by hypoxia-inducible factor 1. Biochem Biophys Res Commun 2002;291:908-14.
30. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-5.
31. Jones MK, Szabo IL, Kawanaka H, et al. Von Hippel Lindau tumor suppressor and HIF-1 alpha: New targets of NSAIDs inhibition of hypoxia-induced angiogenesis. FASEB J 2002;16:264-6.
32. Siemeister G, Weindel K, Mohrs K, et al. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res 1996;56:2299-301.
33. Sanchez-Elsner T, Botella LM, Velasco B, et al. Synergistic cooperation between hypoxia and transforming growth factor-beta pathways on human vascular endothelial growth factor gene expression. J Biol Chem 2001;276:38527-35.
34. Berse B, Hunt JA, Diegel RJ, et al. Hypoxia augments cytokine (transforming growth factor-beta (TGF-beta) and IL-1)-induced vascular endothelial growth factor secretion by human synovial fibroblasts. Clin Exp Immunol 1999;115:176-82.
35. Klagsbrun M, D'Amore PA. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 1996;7:259-70.
36. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996;380:435-9.
37. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380:439-42.
38. Gerber HP, Hillan KJ, Ryan AM, et al. VEGF is required for growth and survival in neonatal mice. Development 1999;126:1149-59.
39. de Vries C, Escobedo JA, Ueno H, et al. The fins-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992;255:989-91.
40. Terman BI, Dougher-Vermazen M, Carrion ME, et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992; 187:1579-86.
41. Klagsbrun M, Moses MA. Molecular angiogenesis. Chem Biol 1999;6:R217-24.
42. Hiratsuka S, Minowa O, Kuno J, et al. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci U S A 1998;95:9349-54.
43. Barleon B, Sozzani S, Zhou D, et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996;87: 3336-43.
44. Wang H, Keiser JA. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: Role of flt-1. Circ Res 1998; 83:832-40.
45. Hattori K, Heissig B, Dias S, et al. Activation of VEGF receptor-1 (VEGFR1, Flt-1) expressed on hematopoietic stem cells promotes cell motility and is essential for marrow reconstitution [abstract 2969]. In: Abstracts of the 43rd Annual Meeting of the American Society of Hematology. Orlando (FL); 2001.
46. Tsiamis AC, Morris PN, Marron MB, et al. Vascular endothelial growth factor modulates the TIE-2:TIE-1 receptor complex. Microvasc Res 2002;63:149-58.
47. Lal BK, Varma S, Pappas PJ, et al. VEGF increases permeability of the endothelial cell monolayer by activation of PKB/akt, endothelial nitric-oxide synthase, and MAP kinase pathways. Microvasc Res 2001;62:252-62.
48. Joussen AM, Poulaki V, Qin W, et al. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol 2002;160:501-9.
49. Lee TH, Avraham H, Lee SH, et al. Vascular endothelial growth factor modulates neutrophil transendothelial migration via upregulation of interleukin-8 in human brain microvascular endothelial cells. J Biol Chem 2002.
50. Soker S, Miao HQ, Nomi M, et al. VEGF(165) mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF(165)-receptor binding. J Cell Biochem 2002;85:357-68.
51. Miao HQ, Lee P, Lin H, et al. Neuropilin-I expression by tumor cells promotes tumor angiogenesis and progression. FASEB J 2000;14:2532-9.
52. Hamada K, Oike Y, Takakura N, et al. VEGF-C signaling pathways through VEGFR-2 and VEGFR-3 in vasculoangiogenesis and hematopoiesis. Blood 2000;96:3793-800.
53. Skobe M, Hamberg LM, Hawighorst T, et al. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol 2001;159:893-903.
54. Skobe M, Hawighorst T, Jackson DG, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001;7:192-8.
55. Stacker SA, Caesar C, Baldwin ME, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001;7:186-91.
56. Bellomo D, Headrick JP, Silins GU, et al. Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ Res 2000;86:E29-35.
57. Conklin BS, Zhao W, Zhong DS, et al. Nicotine and cotinine up-regulate vascular endothelial growth factor expression in endothelial cells. Am J Pathol 2002;160:413-8.
58. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-5.
59. Levy AP, Levy NS, Goldberg MA. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J Biol Chem 1996;271:2746-53.
60. Breier G, Blum S, Peli J, et al. Transforming growth factor-beta and Ras regulate the VEGF/VEGF-receptor system during tumor angiogenesis. Int J Cancer 2002;97:142-8.
61. Masood R, Cesarman E, Smith DL, et al. Human herpesvirus-8-transformed endothelial cells have functionally activated vascular endothelial growth factor/vascular endothelial growth factor receptor. Am J Pathol 2002;160:23-9.
62. Hyder SM, Nawaz Z, Chiappetta C, et al. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res 2000;60:3183-90.
63. Yamamoto T, Kozawa O, Tanabe K, et al. 1,25-Dihydroxyvitamin D3 stimulates vascular endothelial growth factor release in aortic smooth muscle cells: Role of p38 mitogen-activated protein kinase. Arch Biochem Biophys 2002;398:1-6.
64. Wang J, Luo F, Lu JJ, et al. VEGF expression and enhanced production by gonadotropins in ovarian epithelial tumors. Int J Cancer 2002;97:163-7.
65. Nakagami H, Cui TX, Iwai M, et al. Tumor necrosis factor-alpha inhibits growth factor-mediated cell proliferation through SHP-1 activation in endothelial cells. Arterioscler Thromb Vasc Biol 2002;22:238-42.
66. Iliopoulos O, Levy AP, Jiang C, et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A 1996;93:10595-9.
67. Inoki I, Shiomi T, Hashimoto G, et al. Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J 2002;16: 219-21.
68. Basu S, Nagy JA, Pal S, et al. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 2001;7:569-74.
69. Gille J, Reisinger K, Westphal-Varghese B, et al. Decreased mRNA stability as a mechanism of glucocorticoid-mediated inhibition of vascular endothelial growth factor gene expression by cultured keratinocytes. J Invest Dermatol 2001;117:1581-7.
70. Lamy S, Gingras D, Beliveau R. Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation. Cancer Res 2002;62:381-5.
71. Heeschen C, Jang JJ, Weis M, et al. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med 2001;7:833-9.
72. Thurston G, Rudge JS, Ioffe E, et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000;6:460-3.
73. Valenzuela DM, Griffiths JA, Rojas J, et al. Angiopoietins 3 and 4: Diverging gene counterparts in mice and humans. Proc Natl Acad Sci U S A 1999;96:1904-9.
74. Folkman J, D'Amore PA. Blood vessel formation: What is its molecular basis? Cell 1996;87: 1153-5.
75. Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature 2000;407:242-8.
76. Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996;87:1171-80.
77. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994-8.
78. Mustonen T, Alitalo K. Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol 1995;129:895-8.
79. Sato TN, Tozawa Y, Deutsch U, et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995;376:70-4.
80. McCarthy MJ, Crowther M, Bell PR, et al. The endothelial receptor tyrosine kinase tie-1 is upregulated by hypoxia and vascular endothelial growth factor. FEBS Lett 1998;423:334-8.
81. Yabkowitz R, Meyer S, Black T, et al. Inflammatory cytokines and vascular endothelial growth factor stimulate the release of soluble tie receptor from human endothelial cells via metalloprotease activation. Blood 1999;93:1969-79.
82. Kontos CD, Cha EH, York JD, et al. The endothelial receptor tyrosine kinase tie1 activates phosphatidylinositol 3-kinase and akt to inhibit apoptosis. Mol Cell Biol 2002;22:1704-13.
83. Kerbel RS. Tumor angiogenesis: Past, present and the near future. Carcinogenesis 2000;21: 505-15.
84. Chodak GW, Hospelhorn V, Judge SM, et al. Increased levels of fibroblast growth factor-like activity in urine from patients with bladder or kidney cancer. Cancer Res 1988;48:2083-8.
85. Paulus W, Grothe C, Sensenbrenner M, et al. Localization of basic fibroblast growth factor, a mitogen and angiogenic factor, in human brain tumors. Acta Neuropathol (Berl) 1990;79: 418-23.
86. Schulze-Osthoff K, Risau W, Vollmer E, et al. In situ detection of basic fibroblast growth factor by highly specific antibodies. Am J Pathol 1990;137:85-92.
87. Takahashi JA, Fukumoto M, Igarashi K, et al. Correlation of basic fibroblast growth factor expression levels with the degree of malignancy and vascularity in human gliomas. J Neurosurg 1992;76:792-8.
88. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992;3:65-71.
89. Nakamura T, Mochizuki Y, Kanetake H, et al. Signals via FGF receptor 2 regulate migration of endothelial cells. Biochem Biophys Res Commun 2001;289:801-6.
90. Kroon ME, Koolwijk P, van der Vecht B, et al. Hypoxia in combination with FGF-2 induces tube formation by human microvascular endothelial cells in a fibrin matrix: Involvement of at least two signal transduction pathways. J Cell Sci 2001;114:825-33.
91. Mason JC, Lidington EA, Ahmad SR, et al. bFGF and VEGF synergistically enhance endothelial cytoprotection via decay-accelerating factor induction. Am J Physiol Cell Physiol 2002;282:C578-87.
92. Bikfalvi A, Klein S, Pintucci G, et al. Biological roles of fibroblast growth factor-2. Endocr Rev 1997;18:26-45.
93. Folkman J, Klagsbrun M, Sasse J, et al. A heparin-binding angiogenic protein - Basic fibroblast growth factor - Is stored within basement membrane. Am J Pathol 1988;130:393-400.
94. Vlodavsky I, Korner G, Ishai-Michaeli R, et al. Extracellular matrix-resident growth factors and enzymes: Possible involvement in tumor metastasis and angiogenesis. Cancer Metastasis Rev 1990;9:203-26.
95. Yayon A, Klagsbrun M, Esko JD, et al. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 1991;64:841-8.
96. Mason IJ. The ins and outs of fibroblast growth factors. Cell 1994;78:547-52.
97. Sturla LM, Westwood G, Selby PJ, et al. Induction of cell death by basic fibroblast growth factor in Ewing's sarcoma. Cancer Res 2000;60:6160-70.
98. Duplan SM, Theoret Y, Kenigsberg RL. Antitumor activity of fibroblast growth factors (FGFs) for medulloblastoma may correlate with FGF receptor expression and tumor variant. Clin Cancer Res 2002;8:246-57.
99. Wang H, Rubin M, Fenig E, et al. Basic fibroblast growth factor causes growth arrest in MCF-7 human breast cancer cells while inducing both mitogenic and inhibitory G1 events. Cancer Res 1997;57:1750-7.
100. Burchill SA, Westwood G. Mechanism of basic fibroblast growth factor-induced cell death. Apoptosis 2002;7:5-12.
101. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463-516.
102. Khasigov PZ, Podobed OV, Ktzoeva SA, et al. Matrix metalloproteinases of normal human tissues. Biochemistry 2001;66:130-40.
103. Cox G, Jones JL, Andi A, et al. A biological staging model for operable non-small cell lung cancer. Thorax 2001;56:561-6.
104. Duffy MJ, Maguire TM, Hill A, et al. Metalloproteinases: Role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res 2000;2:252-7.
105. Fang J, Shing Y, Wiederschain D, et al. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci U S A 2000;97:3884-9.
106. Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000;19:6642-50.
107. Fielding J. Long term survival data from marimastat phase III clinical trial in patients with gastric cancer (Study 145). In: Abstracts of the 4th Annual International Gastric Cancer Conference. New York (NY); 2001.
108. Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999;285:1028-32.
109. Eliceiri BP, Cheresh DA. Adhesion events in angiogenesis. Curr Opin Cell Biol 2001;13:563-8.
110. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157-64.
111. Brooks PC, Stromblad S, Klemke R, et al. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995;96:1815-22.
112. Kumar CC, Malkowski M, Yin Z, et al. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist. Cancer Res 2001;61:2232-8.
113. Eliceiri BP. Integrin and growth factor receptor crosstalk. Circ Res 2001;89:1104-10.
114. Carmeliet P. Integrin indecision. Nat Med 2002;8:14-6.
115. Reynolds LE, Wyder L, Lively JC, et al. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med 2002;8:27-34.
116. Ruegg C, Yilmaz A, Bieler G, et al. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 1998;4:408-14.
117. Bader BL, Rayburn H, Crowley D, et al. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell 1998;95:507-19.
118. Davis S, Gale NW, Aldrich TH, et al. Ligands for EPH-related receptor tyrosine kinases that require membrane attachment or clustering for activity. Science 1994;266:816-9.
119. Ogawa K, Pasqualini R, Lindberg RA, et al. The ephrin-A1 ligand and its receptor. EphA2, are expressed during tumor neovascularization. Oncogene 2000;19:6043-52.
120. Dong Z, Kumar R, Yang X, et al. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 1997;88:801-10.
121. Stathakis P, Fitzgerald M, Matthias LJ, et al. Generation of angiostatin by reduction and proteolysis of plasmin. Catalysis by a plasmin reductase secreted by cultured cells. J Biol Chem 1997;272:20641-5.
122. Lucas R, Holmgren L, Garcia I, et al. Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood 1998;92:4730-41.
123. Ito H, Rovira II, Bloom ML, et al. Endothelial progenitor cells as putative targets for angiostatin. Cancer Res 1999;59:5875-7.
124. Ji WR, Barrientos LG, Llinas M, et al. Selective inhibition by kringle 5 of human plasminogen on endothelial cell migration, an important process in angiogenesis. Biochem Biophys Res Commun 1998;247:414-9.
125. Moser TL, Stack MS, Asplin I, et al. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci U S A 1999;96:2811-6.
126. Troyanovsky B, Levchenko T, Mansson G, et al. Angiomotin: An angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol 2001;152: 1247-54.
127. Cassatella MA. The production of cytokines by polymorphonuclear neutrophils. Immunol Today 1995;16:21-6.
128. Benelli R, Morini M, Carrozzino F, et al. Neutrophils as a key cellular target for angiostatin: Implications for regulation of angiogenesis and inflammation. FASEB J 2002;16:267-9.
129. Moser TL, Kenan DJ, Ashley TA, et al. Endothelial cell surface F1-F0 ATP synthase is active in ATP synthesis and is inhibited by angiostatin. Proc Natl Acad Sci U S A 2001;98: 6656-61.
130. Shichiri M, Hirata Y. Antiangiogenesis signals by endostatin. FASEB J 2001;15:1044-53.
131. Rehn M, Pihlajaniemi T. Identification of three N-terminal ends of type XVIII collagen chains and tissue-specific differences in the expression of the corresponding transcripts. The longest form contains a novel motif homologous to rat and Drosophila frizzled proteins. J Biol Chem 1995;270:4705-11.
132. Ferreras M, Felbor U, Lenhard T, et al. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett 2000;486:247-51.
133. Hanai JJ, Dhanabal M, Karumanchi SA, et al. Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem 2002;277:16464-9.
134. Dixelius J, Larsson H, Sasaki T, et al. Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood 2000;95:3403-11.
135. MacDonald NJ, Shivers WY, Narum DL, et al. Endostatin binds tropomyosin. A potential modulator of the antitumor activity of endostatin. J Biol Chem 2001;276:25190-6.
136. Schuch G, Machluf M, Nomi M, et-al. Endostatin inhibits mobilization of bone marrow-derived endothelial progenitor cells [abstract]. In: Abstracts of the American Society of Hematology 43rd Annual Meeting. Orlando (FL); 2001.
137. Berger AC, Feldman AL, Gnant MF, et al. The angiogenesis inhibitor, endostatin, does not affect murine cutaneous wound healing. J Surg Res 2000;91:26-31.
138. Bloch W, Huggel K, Sasaki T, et al. The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing. FASEB J 2000;14:2373-6.
139. Nemoto T, Hori H, Yoshimoto M, et al. Overexpression of oithine decarboxylase enhances endothelial proliferation by suppressing endostatin expression. Blood 2002;99:1478-81.
140. Good DJ, Polverini PJ, Rastinejad F, et al. A tumor suppressor-dependent inhibitor of anglogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A 1990;87:6624-8.
141. Volpert OV, Tolsma SS, Pellerin S, et al. Inhibition of angiogenesis by thrombospondin-2. Biochem Biophys Res Commun 1995;217:326-32.
142. Adams JC. Thrombospondins: Multifunctional regulators of cell interactions. Annu Rev Cell Dev Biol 2001;17:25-51.
143. Guo N, Krutzsch HC, Inman JK, et al. Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res 1997; 57:1735-42.
144. Volpert OV, Zaichuk T, Zhou W, et al. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 2002;8:349-57.
145. Wick W, Petersen I, Schmutzler RK, et al. Evidence for a novel tumor suppressor gene on chromosome 15 associated with progression to a metastatic stage in breast cancer. Oncogene 1996;12:973-8.
146. Bockmuhl U, Petersen S, Schmidt S, et al. Patterns of chromosomal alterations in metastasizing and nonmetastasizing primary head and neck carcinomas. Cancer Res 1997;57:5213-6.
147. Bleuel K, Popp S, Fusenig NE, et al. Tumor suppression in human skin carcinoma cells by chromosome 15 transfer or thrombospondin-1 overexpression through halted tumor vascularization. Proc Natl Acad Sci U S A 1999;96:2065-70.
148. Streit M, Velasco P, Brown LF, et al. Overexpression of thrombospondin-1 decreases anglogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am J Pathol 1999;155:441-52.
149. Streit M, Riccardi L, Velasco P, et al. Thrombospondin-2: A potent endogenous inhibitor of tumor growth and angiogenesis. Proc Natl Acad Sci U S A 1999;96:14888-93.
150. Rofstad EK, Graft BA. Thrombospondin-1-mediated metastasis suppression by the primary tumor in human melanoma xenografts. J Invest Dermatol 2001;117:1042-9.
151. Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, et al. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 1994;54:6504-11.
152. Reiher FK, Volpert OV, Jimenez B, et al. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int J Cancer 2002;98:682-9.
153. Castle V, Varani J, Fligiel S, et al. Antisense-mediated reduction in thrombospondin reverses the malignant phenotype of a human squamous carcinoma. J Clin Invest 1991;87:1883-8.
154. Eckhardt SG. Angiogenesis inhibitors as cancer therapy. Hosp Pract (Off Ed) 1999;34:63-84.
155. Molica S, Vitelli G, Levato D, et al. Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in early B-cell chronic lymphocytic leukaemia. Br J Cancer 2002;86:31-5.
156. Bertolini F, Paolucci M, Peccatori F, et al. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol 1999;106:504-9.
157. Salven P, Orpana A, Teerenhovi L, et al. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin's lymphoma: A single-institution study of 200 patients. Blood 2000;96:3712-8.
158. Kuramoto K, Sakai A, Shigemasa K, et al. High expression of MCL1 gene related to vascular endothelial growth factor is associated with poor outcome in non-Hodgkin's lymphoma. Br J Haematol 2002;116:158-61.
159. Giles FJ, Vose JM, Manshouri T, et al. Clinical relevance of angiogenesis-modulating factors in patients with Hodgkin's disease and non-Hodgkin's lymphoma [abstract]. In: Abstracts of the 43rd Annual Meeting of the American Society of Hematology. Orlando (FL);2001.
160. Shimada H, Hoshino T, Okazumi S, et al. Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma. Br J Cancer 2002;86:552-7.
161. Barozzi C, Ravaioli M, D'Errico A, et al. Relevance of biologic markers in colorectal carcinoma: A comparative study of a broad panel. Cancer 2002;94:647-57.
162. Herrera CA, Xu L, Bucana CD, et al. Expression of metastasis-related genes in human epithelial ovarian tumors. Int J Oncol 2002;20:5-13.
163. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-70.
164. Karashima T, Sweeney P, Slaton JW, et al. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin Cancer Res 2002;8:1253-64.
165. Perrotte P, Matsumoto T, Inoue K, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999;5:257-65.
166. Bruns CJ, Solorzano CC, Harbison MT, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000;60:2926-35.
167. Baker CH, Solorzano CC, Fidler IJ. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res 2002;62:1996-2003.
168. Abbruzzese JL, Rosenberg A, Xiong Q, et al. Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer [abstract]. In: Abstracts of the 37th Annual Meeting of ASCO. San Francisco (CA); 2001.
169. Baselga J, Trigo JM, Bourhis J. Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen. In: Abstracts of the 38th Annual Meeting of ASCO. Orlando (FL); 2002.
170. Gunnett K, Motzer R, Amato R, et al. Phase II study of anti-epidermal growth factor receptor antibody C225 alone in patients with metastatic renal cell carcinoma [abstract]. In: Abstracts of the 35th Annual Meeting of ASCO. Atlanta (GA); 1999.
171. Kim ES, Mauer AM, Fossella FV, et al. A phase II study of Erbitux (IMC-C225), an epidermal growth factor receptor blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer [abstract]. In: Abstracts of the 38th Annual Meeting of ASCO. Orlando (FL); 2002.
172. Kris MG, Natale RB, Herbst RS, et al. A phase II trial of ZD1839 ('Iressa') in advanced nonsmall cell lung cancer patients who had failed platinum- and docetaxel-based regimens (IDEAL 2) [abstract]. In: Abstracts of the 38th Annual Meeting of ASCO. Orlando (FL); 2002.
173. Saltz L, Meropol NJ, Loehrer PJ, et al. Single agent IMC-C225 (Erbitux™) has activity in CPT-11-refractory colorectal cancer that expresses the epidermal growth factor receptor [abstract]. In: Abstracts of the 38th Annual Meeting of ASCO. Orlando (FL); 2002.
174. Brown LF, Berse B, Jackman RW, et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 1993;143:1255-62.
175. Otani N, Minami S, Yamoto M, et al. The vascular endothelial growth factor/fms-like tyrosine kinase system in human ovary during the menstrual cycle and early pregnancy. J Clin Endocrinol Metab 1999;84:3845-51.
176. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 2001;280:C1358-66.
177. Achilles EG, Fernandez A, Allred EN, et al. Heterogeneity of angiogenic activity in a human liposarcoma: A proposed mechanism for "no take" of human tumors in mice. J Natl Cancer Inst 2001;93:1075-81.
178. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-4.
179. Millauer B, Shawver LK, Plate KH, et al. Glioblastoma growth inhibited in vivo by a dominantnegative Flk-1 mutant. Nature 1994;367:576-9.
180. Warren RS, Yuan H, Matli MR, et al. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995;95:1789-97.
181. Giantonio BJ, Levy D, Catalano PJ, et al. Incorporating angiogenesis inhibition with bevacizumab (anti-VEGF) into frontline chemotherapy with irinotecan, fluorouracil and leucovorin for advanced colorectal cancer: A toxicity analysis of ECOG study E2200 [abstract]. In: Abstracts of the 38th Annual Meeting of ASCO. Orlando (FL); 2002.
182. Margolin K, Gordon MS, Holmgren E, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data. J Clin Oncol 2001;19:851-6.
183. DeVore RF, Fehrenbacher L, Herbst RS, et al. A randomized phase 11 trial comparing Rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC [abstract]. In: Abstracts of the 36th Annual Meeting of ASCO. New Orleans (LA);2000.
184. Novotny WF, Holmgren E, Griffing S, et al. Identification of squamous cell histology and central, cavitary tumors as possible risk factors for pulmonary hemorrhage (PH) in patients with advanced NSCLC receiving bevacizumab (BV) [abstract]. In: Abstracts of the 37th Annual Meeting of ASCO. San Francisco (CA); 2001.
185. Bergsland EK, Fehrenbacher L, Novotny W, et al. Bevacizumab + chemotherapy may improve survival in metastatic colorectal cancer subjects with unfavorable prognostic indicators [abstract]. In: Abstracts of the 37th Annual Meeting of ASCO. San Francisco (CA); 2001.
186. National Cancer Institute. Search for Clinical Trials with Antiangiogenic Agents. Available at: http://www.cancer.gov/search/clinical.trials/2001. Accessed April 6, 2002.
187. Yang JC, Haworth L, Steinberg SM, et al. A randomized double-blind placebo-controlled trial of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer [abstract]. In: Abstracts of the 38th Annual Meeting of ASCO. Orlando (FL); 2002.
188. Bergsland E, Hurwitz H, Fehrenbacher L, et al. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluorouracil/leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer [abstract]. In: Abstracts of the 36th Annual Meeting of ASCO. New Orleans (LA); 2000.
189. Sledge G, Miller K, Novotny W, et al. A phase II trial of single-agent Rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) in patients with relapsed metastatic breast cancer [abstract]. In: Abstracts of the 36th Annual Meeting of ASCO. New Orleans (LA); 2000.
190. Kabbinavar FF, Johnson D, Langmuir VK, et al. Patterns of tumor progression during therapy with bevacizumab (BV) and chemotherapy (CT) for metastatic colorectal cancer (MCRC) and advanced non-small cell lung cancer (NSCLC) [abstract 1105]. In: Abstracts of the 37th Annual Meeting of ASCO. San Francisco (CA); 2001.
191. Johnson DH, DeVore RF, Kabbinavar F, et al. Carboplatin (C) + paclitaxel (T) + RhuMabVEGF (AVF) may prolong survival in advanced non-squamous lung cancer [abstract]. In: Abstracts of the 37th Annual Meeting of ASCO. San Francisco (CA); 2001.
192. Langmuir VK, Cobleigh MA, Herbst RS, et al. Successful long-term therapy with bevaeizumab (Avastin) in solid tumors [abstract]. In: Abstracts of the 38th Annual Meeting of ASCO. Orlando (FL); 2002.
193. Dias S, Hattori K, Zhu Z, et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest 2000;106:511-21.
194. Hunt S. Technology evaluation: IMC-1C11, ImClone Systems. Curr Opin Mol Ther 2001;3: 418-24.
195. Posey J, Ng T, Yang B, et al. A phase I trial of an anti-KDR (VEGFR) chimeric antibody in patients with liver metastases in colorectal cancer (CRC). In: Abstracts of the 38th Annual Meeting of ASCO. Orlando, (FL); 2002.
196. Mendel DB, Laird AD, Smolich BD, et al. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des 2000;15:29-41.
197. O'Farrell A, Yuen HA, Louie SG, et al. Analysis of mechanism of action and biomarkers for kinase inhibitor SU5416 in AML patients [abstract]. In: Abstracts of the 38th Annual Meeting of ASCO. Orlando (FL); 2002.
198. Laird AD, Vajkoczy P, Shawver LK, et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 2000;60:4152-60.
199. Liu G, Eskin SG, Mikos AG. Integrin alpha(v)beta(3) is involved in stimulated migration of vascular adventitial fibroblasts by basic fibroblast growth factor but not platelet-derived growth factor. J Cell Biochem 2001;83:129-35.
200. Rosenkranz S, Kazlauskas A. Evidence for distinct signaling properties and biological responses induced by the PDGF receptor alpha and beta subtypes. Growth Factors 1999;16: 201-16.
201. Smolich BD, Yuen HA, West KA, et al. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood 2001;97:1413-21.
202. Sugen. 2002 News. Available at: http://www.sugen.com/webpage.templates/sec.php3?page.name=press. Accessed March 29, 2002.
203. Rosen LS, Rosen PJ, Kabbinavar F, et al. Phase I experience with SU6668, a novel multiple receptor tyrosine kinase inhibitor in patients with advanced malignancies [abstract]. In: Abstracts of the 37th Annual Meeting of ASCO. San Francisco (CA); 2001.
204. Rosen LS, Hannah A, Rosen PJ, et al. Phase 1 dose-escalating trial of oral SU6668, a novel multiple receptor tyrosine kinase inhibitor in patients with selected advanced malignancies [abstract]. In: Abstracts of the 36th Annual Meeting of ASCO. New Orleans (LA); 2000.
205. Griffin RJ, Williams BW, Wild R, et al. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Res 2002;62:1702-6.
206. Britten CD, Rosen LS, Kabbinavar F, et al. Phase I trial of SU6668, a small molecule receptor tyrosine kinase inhibitor, given twice daily in patients with advanced cancers [abstract]. In: Abstracts of the 38th Annual Meeting of ASCO. Orlando (FL); 2002.
207. Drevs J, Hofmann I, Hugenschmidt H, et al. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 2000;60: 4819-24.
208. Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000;60:2178-89.
209. Hess C, Vuong V, Hegyi I, et al. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. Br J Cancer 2001;85:2010-6.
210. Drevs J, Mross K, Fuxius S, et al. A phase-1 dose-escalating and pharmacokinetic study of the VEGF-receptor-inhibitor PTK787/ZK222584 in patients with liver metastasis of advanced cancer [abstract]. In: Abstracts of the 37th Annual Meeting of ASCO. San Francisco (CA); 2001.
211. Yung WKA, Friedman H, Jackson E, et al. A phase I trial of PTK787/ZK 222584 (PTK/ZK), a novel oral VEGFR TK inhibitor in recurrent glioblastoma [abstract]. In: Abstracts of the 38th Annual Meeting of ASCO. Orlando (FL); 2002.
212. Hennequin LF, Stokes ES, Thomas AP, et al. Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J Med Chem 2002;45:1300-12.
213. Wedge SR, Ogilvie DJ, Dukes M, et al. Chronic and acute effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, on established human tumour xenografts [abstract]. In: Abstracts of the 11th NCI-EORTC-AACR Symposium. Amsterdam; 2000.
214. Basser R, Hurwitz H, Barge A, et al. Phase 1 pharmacokinetic and biological study of the angiogenesis inhibitor, ZD6474, in patients with solid tumors [abstract]. In: Abstracts of the 37th Annual Meeting of ASCO. San Francisco (CA); 2001.
215. Hurwitz H, Holden SN, Eckhardt SG, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling, in patients with solid tumors. In: Abstracts of the 38th Annual Meeting of ASCO. Orlando (FL); 2002.
216. AG013736 - Investigator's brochure. Pfizer Inc. and Affiliates. October 19, 2001.
217. Gutheil JC, Campbell TN, Pierce PR, et al. Targeted antiangiogenic therapy for cancer using Vitaxin: A humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 2000; 6:3056-61.
218. Patel SR, Jenkins J, Papadopolous N, et al. Pilot study of vitaxin-an angiogenesis inhibitor-in patients with advanced leiomyosarcomas. Cancer 2001;92:1347-8.
219. Posey JA, Khazaeli MB, DelGrosso A, et al. A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. Cancer Biother Radiopharm 2001;16:125-32.
220. MacDonald TJ, Taga T, Shimada H, et al. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery 2001;48:151-7.
221. Eskens F, Dumez H, Verweij J, et al. Phase 1 and pharmacologic study of EMD 121974, an alpha3beta5 integrin inhibitor that perturbs tumor angiogenesis, in patients with solid tumors [abstract]. In: Abstracts of the 36th Annual Meeting of ASCO. New Orleans (LA); 2000.
222. Holden SN, Morrow M, O'Bryant C, et al. Correlative biological assays used to guide dose escalation in a phase I study of the antiangiogenic aVβ3 and aVβ5 integrin antagonist EMD 121974 [abstract]. In: Abstracts of the 38th Annual Meeting of ASCO. Orlando (FL); 2002.
223. Cianchi F, Cortesini C, Bechi P, et al. Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 2001;121: 1339-47.
224. Jaeckel EC, Raja S, Tan J, et al. Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferator-activated receptor delta with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2001;127:1253-9.
225. Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 2001;7:861-7.
226. Kirschenbaum A, Liu X, Yao S, et al. The role of cyclooxygenase-2 in prostate cancer. Urology 2001;58:127-31.
227. Yoshimura R, Sano H, Mitsuhashi M, et al. Expression of cyclooxygenase-2 in patients with bladder carcinoma. J Urol 2001;165:1468-72.
228. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252-66.
229. Garcia Rodriguez LA, Huerta-Alvarez C. Reduced incidence of colorectal adenoma among long-term users of nonsteroidal antiinflammatory drugs: A pooled analysis of published studies and a new population-based study. Epidemiology 2000;11:376-81.
230. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994;5:138-46.
231. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-6.
232. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52.
233. Leahy KM, Ornberg RL, Wang Y, et al. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002;62:625-31.
234. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
235. Dormond O, Foletti A, Paroz C, et al. NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat Med 2001;7:1041-7.
236. Lin EH, Morris J, Chau NK, et al. Celecoxib attenuated capecitabine induced hand-and-foot syndrome and diarrhea and improved time to tumor progression in metastatic colorectal cancer [abstract]. In: Abstracts of the 38th Annual Meeting of ASCO. Orlando (FL); 2002.
237. Sweeney C, Seitz D, Ansari R, et al. A phase II trial of irinotecan, 5-fluorouracil, leucovorin, celecoxib and glutamine as first line therapy for advanced colorectal cancer: a Hoosier Oncology Group study [abstract]. In: Abstracts of the 38th Annual Meeting of ASCO. Orlando (FL); 2002.
238. Blanke CD, Benson III AB, Dragovich T, et al. A phase II trial of celecoxib, irinotecan, 5-fluorouracil, and leucovorin in patients with unresectable or metastatic colorectal cancer [abstract]. In: Abstracts of the 38th Annual Meeting of ASCO. Orlando (FL); 2002.
239. Altorki NK, Keresztes RS, Port JL, et al. Celecoxib (Celebrex), a selective COX-2 inhibitor, enhances the response to preoperative paclitaxel/carboplatin in early stage non-small cell lung cancer [abstract]. In: Abstracts of the 38th Annual Meeting of ASCO. Orlando (FL); 2002.
240. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-9.
241. Blezinger P, Wang J, Gondo M, et al. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat Biotechnol 1999;17: 343-8.
242. Peroulis I, Jonas N, Saleh M. Antiangiogenic activity of endostatin inhibits c6 glioma growth. Int J Cancer 2002;97:839-45.
243. Sauter BV, Martinet O, Zhang WJ, et al. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc Natl Acad Sci U S A 2000;97:4802-7.
244. Eder JP, Clark JW, Supko JG, et al. A phase I pharmacokinetic and pharmacodynamic trial of recombinant human endostatin [abstract]. In: Abstracts of the 37th Annual Meeting of ASCO. San Francisco (CA); 2001.
245. Herbst RS, Tran HT, Mullani NA, et al. Phase I clinical trial of recombinant human endostatin (rHE) in patients with solid tumors: Pharmacokinetic, safety and efficacy analysis using surrogate endpoints of tissue and radiologic response [abstract ]. In: Abstracts of the 37th Annual Meeting of ASCO. San Francisco (CA); 2001.
246. Mundhenke C, Thomas JP, Wilding G, et al. Tissue examination to monitor antiangiogenic therapy: A phase I clinical trial with endostatin. Clin Cancer Res 2001;7:3366-74.
247. Joki T, Machluf M, Atala A, et al. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat Biotechnol 2001;19:35-9.
248. Eder JP, Clark J, Supko J, et al. A phase I trial of recombinant human endostatin [abstract]. In: Abstracts of the 38th Annual Meeting of ASCO. Orlando (FL); 2002.
249. DeMoraes ED, Fogler WE, Grant D, et al. Recombinant human angiostatin: A phase I clinical trial assessing safety, pharmacokinetics and pharmacodynamics [abstract]. In: Abstracts of the 37th Annual Meeting of ASCO. San Francisco (CA); 2001.
250. Voest EE, Beerepoot LV, Groenewegen G, et al. Phase I trial of recombinant human angiostatin by twice-daily subcutaneous injection in patients with advanced cancer [abstract]. In: Abstracts of the 38th Annual Meeting of ASCO. Orlando (FL); 2002.
251. Catalano A, Romano M, Robuffo I, et al. Methionine aminopeptidase-2 regulates human mesothelioma cell survival: Role of Bcl-2 expression and telomerase activity. Am J Pathol 2001;159:721-31.
252. Turk BE, Griffith EC, Wolf S, et al. Selective inhibition of amino-terminal methionine processing by TNP-470 and ovalicin in endothelial cells. Chem Biol 1999;6:823-33.
253. Yeh JR, Mohan R, Crews CM. The antiangiogenic agent TNP-470 requires p53 and p21CIP/WAF for endothelial cell growth arrest. Proc Natl Acad Sci U S A 2000;97:12782-7.
254. Beecken WD, Fernandez A, Panigrahy D, et al. Efficacy of antiangiogenic therapy with TNP-470 in superficial and invasive bladder cancer models in mice. Urology 2000;56: 521-6.
255. Gervaz P, Scholl B, Padrun V, et al. Growth inhibition of liver metastases by the anti-angiogenic drug TNP-470. Liver 2000;20:108-13.
256. Hotz HG, Reber HA, Hotz B, et al. Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth. J Gastrointest Surg 2001;5:131-8.
257. Kato H, Ishikura H, Kawarada Y, et al. Anti-angiogenic treatment for peritoneal dissemination of pancreas adenocarcinoma: A study using TNP-470. Jpn J Cancer Res 2001;92:67-73.
258. Kawano T, Yanoma S, Nishimura G, et al. The inhibitory effects of TNP470 on tumour growth of head and neck carcinoma cell producing interleukin-8. J Laryngol Otol 2001; 115:802-7.
259. Landuyt W, Theys J, Nuyts S, et al. Effect of TNP-470 (AGM-1470) on the growth of rat rhabdomyosarcoma tumors of different sizes. Cancer Invest 2001;19:35-40.
260. Shusterman S, Grupp SA, Barr R, et al. The angiogenesis inhibitor tnp-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease. Clin Cancer Res 2001;7:977-84.
261. Hausman MR, Schaffler MB, Majeska RJ. Prevention of fracture healing in rats by an inhibitor of angiogenesis. Bone 2001;29:560-4.
262. Klein SA, Bond SJ, Gupta SC, et al. Angiogenesis inhibitor TNP-470 inhibits murine cutaneous wound healing. J Surg Res 1999;82:268-74.
263. Bhargava P, Marshall JL, Rizvi N, et al. A phase 1 and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin Cancer Res 1999;5:1989-95.
264. Logothetis CJ, Wu KK, Finn LD, et al. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin Cancer Res 2001;7:1198-203.
265. Dezube BJ, Von Roenn JH, Holden-Wiltse J, et al. Fumagillin analog in the treatment of Kaposi's sarcoma: A phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. J Clin Oncol 1998;16:1444-9.
266. Kudelka AP, Levy T, Verschraegen CF, et al. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin Cancer Res 1997;3:1501-5.
267. Stadler WM, Kuzel T, Shapiro C, et al. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol 1999;17:2541-5.
268. Richardson P, Hideshima T, Anderson K. Thalidomide: Emerging role in cancer medicine. Annu Rev Med 2002;53:629-57.
269. Garcia A, Gordon A, Markman M, et al. Phase I/II Trial of IM862, a novel immunomodulator with anti-angiogenic activity, in patients with recurrent ovarian cancer [abstract]. In: Abstracts of the 37th Annual Meeting of ASCO. San Francisco (CA); 2001.
270. Tulpule A, Scadden DT, Espina BM, et al. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol 2000;18:716-23.
271. Cytran announces preliminary results of phase III KS trial. Business wire. Kirkland, (WA); August 17, 2001.
272. Dupont E, Falardeau P, Mousa SA, et al. Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue. Clin Exp Metastasis 2002;19:145-53.
273. Gingras D, Renaud A, Mousseau N, et al. Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound. Anticancer Res 2001;21:145-55.
274. Franqois B, Jourdes P, Benabid A. Æ-941 (neovastat) induces the expression of angiostatin in experimental glioma [abstract]. In: Abstracts of the 37th Annual Meeting of ASCO. San Francisco (CA); 2001.
275. Batist G, Champagne P, Hariton C, et al. Dose-survival relationship in a phase II study of neovastat in refractory renal cell carcinoma patients [abstract]. In: Abstracts of the 38th Annual Meeting of ASCO. Orlando (FL); 2002.
276. Francois B, Champagne P, Evans WK, et al. Phase I/II trials on the safety, tolerability and efficacy of Æ-941 (neovastat) in patients with solid tumors [abstract]. In: Abstracts of the 37th Annual Meeting of ASCO. San Francisco (CA); 2001.
277. Weber MH, Lee J, Orr FW. The effect of Neovastat (AE-941) on an experimental metastatic bone tumor model. Int J Oncol 2002;20:299-303.
278. Richardson PG, Berenson J, Irwin D, et al. Phase II study of PS-341, a novel proteasome inhibitor, alone or in combination with dexamethasone in patients with multiple myeloma who have relapsed following front-line therapy and are refractory to their most recent therapy [abstract]. In: Abstracts of the 43rd Annual Meeting of the American Society of Hematology. Orlando (FL); 2001.
279. Scappaticci FA, Sainath P, Contreras A, et al. Induction of anti-tumor immunity in mice using a syngeneic endothelial cell vaccine [abstract]. In: Abstracts of the 43rd Annual Meeting of the American Society of Hematology. Orlando (FL); 2001.
280. Gonzalez GM, Crombet T, Torres F, et al. Epidermal growth factor based cancer vaccine for non small cell lung cancer therapy. Characterization of the obtained immune response and relation with improved survival [abstract]. In: Abstracts of the 37th Annual Meeting of ASCO. San Francisco (CA); 2001.
281. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 1996;380:364-6.
282. Arap W, Haedicke W, Bemasconi M, et al. Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci U S A 2002;99:1527-31.
283. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279:377-80.
284. Arap W, Kolonin MG, Trepel M, et al. Steps toward mapping the human vasculature by phage display. Nat Med 2002;8:121-7.
285. Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999;59:3374-8.
286. Gorski DH, Mauceri HJ, Salloum RM, et al. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res 1998;58:5686-9.
287. Hanna NN, Seetharam S, Mauceri HJ, et al. Antitumor interaction of short-course endostatin and ionizing radiation. Cancer J 2000;6:287-93.
288. Mauceri HJ, Hanna NN, Beckett MA, et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 1998;394:287-91.
289. Ning S, Laird D, Cherrington JM, et al. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat Res 2002;157:45-51.
290. Mullani N, Herbst R, Abbruzzese J, et al. 9:00-9:15. Antiangiogenic treatment with endostatin results in uncoupling of blood flow and glucose metabolism in human tumors. Clin Positron Imaging 2000;3:151.
291. Lee CG, Heijn M, di Tomaso E, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000; 60:5565-70.
292. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-86.
293. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15-24.
294. Burstein HJ, Manola J, Younger J, et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000;18:1212-9.
295. Greco FA. Docetaxel (Taxotere) administered in weekly schedules. Semin Oncol 1999;26: 28-31.
296. Colleoni M, Rocca A, Sandri MT, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: Antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002;13:73-80.
297. Yu JL, Rak JW, Coomber BL, et al. Effect of p53 status on tumor response to antiangiogenic therapy. Science 2002;295:1526-8.
298. Tosetti F, Ferrari N, De Flora S, et al. Angioprevention: Angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 2002;16:2-14.
299. Perletti G, Concari P, Giardini R, et al. Antitumor activity of endostatin against carcinogen-induced rat primary mammary tumors. Cancer Res 2000;60:1793-6.